Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial

Hsieh, Jen-Tsung; Hsu, Cheng Lung; Ng, Shu Hang; Wang, Cheng‐Hsu; Lee, Kuan Der; Lu, Chang; Chang, Yi; Hsieh, Ruey Kuen; Yeh, Kun‐Huei; Hsiao, Ching Hua; Chen, Sheng Yu; Shiau, Cheng Ying; Wang, Hung Ming

doi:10.1093/jjco/hyv083

Cited by 21 publications

(20 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Population-based data appear to support the role of earlier RT in the management of metastatic disease. 42 Active combination regimens for these patients include gemcitabine/cisplatin (category 1) 43,44 ; cisplatin or carboplatin, plus a taxane 45,46 ; cisplatin/5-FU 46,47 ; or carboplatin/cetuximab. 48 Results from a trial that compared 5 different cisplatin-based regimens for NPC showed that a gemcitabine/cisplatin regimen was effective, although not better than either cisplatin/5-FU or cisplatin/paclitaxel.…”

Section: Metastatic Diseasementioning

confidence: 99%

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

Colevas¹,

Yom²,

Pfister³

et al. 2018

J Natl Compr Canc Netw

477

411

View full text Add to dashboard Cite

The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the H&N, and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding evaluation and treatment of nasopharyngeal carcinoma.

show abstract

Section: Metastatic Diseasementioning

confidence: 99%

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

Colevas¹,

Yom²,

Pfister³

et al. 2018

J Natl Compr Canc Netw

477

411

View full text Add to dashboard Cite

show abstract

“…Approximately 80% of all TCCs initially develop along the superficial papillary pathway; the remaining 20% develop along the non‐papillary pathway and are at a high risk of progressing towards muscle invasive disease with a substantial risk for the development of distant metastasis . The current standard of care for this metastatic disease includes a combination of gemcitabine and cisplatin . Apart from this new combinatorial regimen of traditional chemotherapeutic drugs, no new drugs for bladder cancer have entered the market in nearly 30 years.…”

Section: Introductionmentioning

confidence: 99%

Targeted inhibition of Polo‐like kinase 1 by a novel small‐molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells

Zhang

Kong

2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

Bladder cancer is a common cancer with particularly high recurrence after transurethral resection. Despite improvements in neoadjuvant chemotherapy, the outcome of patients with advanced bladder cancer has changed very little. In this study, the anti‐tumour activities of a novel Polo‐like kinase 1 (PLK1) inhibitor (RO3280) was evaluated in vitro and in vivo in the bladder carcinoma cell lines 5637 and T24. MTT assays, colony‐formation assays, flow cytometry, cell morphological analysis and trypan blue exclusion assays were used to examine the proliferation, cell cycle distribution and apoptosis of bladder carcinoma cells with or without RO3280 treatment. Moreover, real‐time RT‐PCR and Western blotting were used to detect the expressions of genes that are related to these cellular processes. Our results showed that RO3280 inhibited cell growth and cell cycle progression, increased Wee1 expression and cell division cycle protein 2 phosphorylation. In addition, RO3280 induced mitotic catastrophe and apoptosis, increased cleaved PARP (poly ADP‐ribose polymerase) and caspase‐3, and decreased BubR1 expression. The in vivo assay revealed that RO3280 retarded bladder cancer xenograft growth in a nude mouse model. Although further laboratory and pre‐clinical investigations are needed to corroborate these data, our demonstration of bladder cancer growth inhibition and dissemination using a pharmacological inhibitor of PLK1 provides new opportunities for future therapeutic intervention.

show abstract

“…Between 2002 and 2015, to confirm the synergistic effect of gemcitabine and platinum in vitro , four small, phase-2 trials reported the results of a GC regimen or gemcitabine plus oxaliplatin regimen in patients with recurrent NPC or M-NPC [13] , [14] , [15] , [16] . In 2002, Ngan et al [13] reported a response rate of 73% and a median PFS of 10.6 (range, 8.5-12.6) months for 44 patients who received salvage chemotherapy with a GC regimen.…”

Section: Discussionmentioning

confidence: 99%

“…In 2009, Ma et al [15] reported a response rate of 56.1% and a median PFS of 9 (range, 7.3-10) months for 42 patients who received salvage chemotherapy with a gemcitabine plus oxaliplatin regimen. In 2015, Hsieh and colleagues [16] reported a response rate of 51.9% and a median PFS of 9.8 (range, 6.5-13.0) months for 52 patients who received salvage chemotherapy with a GC regimen. In 2016, Zhang and colleagues [8] presented the results of the first randomized, multicenter, open-label, phase-3 trial comparing the efficacy and safety of GC versus fluorouracil plus cisplatin in patients with recurrent NPC or M-NPC.…”

Section: Discussionmentioning

confidence: 99%

Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update

Jin

Jiang

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

OBJECTIVE: A previous phase-2 trial to assess the addition of Endostar to gemcitabine and cisplatin (GC) chemotherapy showed that it improves prognosis in metastatic nasopharyngeal carcinoma (M-NPC) but the study cohort was small. We wished to update that phase-2 trial by enrolling an additional 44 patients and to assess the benefit of Endostar+GC chemotherapy. METHODS: An analysis of 72 M-NPC patients treated between July 2010 and November 2016 was done. The treatment regimen was a combination of gemcitabine (1,000 mg/m2) on days 1 and 8, cisplatin (80 mg/m2) on day 1, and Endostar (15 mg/day) from day 1 to day 14 of a 21-day cycle for ≥2 cycles. The acute toxic effects and therapeutic efficacy were analyzed. RESULTS: The response rate was 77.8%. The median progression-free and overall survivals were 12 and 19.5 months, respectively. A total of 329 cycles of GC and 288 cycles of Endostar were delivered to 72 patients, with the median number of four (range, 2–10) cycles administered per patient. The main grade-3/4 hematologic toxicities were leukopenia (54.1%) and neutropenia (59.8%). The number of non-hematologic adverse events was minimal. The regimen was well-tolerated. CONCLUSIONS: Endostar+GC chemotherapy is an effective, well-tolerated regimen for M-NPC.

show abstract

Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial

Abstract: Gemcitabine plus cisplatin is an effective, well-tolerated regimen as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma.

Cited by 21 publications

References 45 publications

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

Targeted inhibition of Polo‐like kinase 1 by a novel small‐molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells

Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update

Contact Info

Product

Resources

About